Y mAbs Therapeutics (YMAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Y mAbs Therapeutics (YMAB) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.65 Million) by net assets ($87.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See YMAB net asset quality score to measure how much of total assets are equity-financed.
Y mAbs Therapeutics - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Y mAbs Therapeutics cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Y mAbs Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Y mAbs Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Berto Acquisition Corp. Ordinary Shares
NASDAQ:TACO
|
0.000x |
|
Tsogo Sun
JSE:TSG
|
0.196x |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
0.002x |
|
American Exceptionalism Acquisition Corp. A
NYSE:AEXA
|
0.000x |
|
Lifeway Foods Inc
NASDAQ:LWAY
|
0.003x |
|
Amex Exploration Inc
V:AMX
|
-0.002x |
|
Instone Real Estate Group AG
XETRA:INS
|
-0.012x |
|
China Bicycle Co Holdings Ltd
SHE:000017
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Y mAbs Therapeutics (2016–2024)
The table below shows the annual cash flow conversion efficiency of Y mAbs Therapeutics from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see YMAB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.00 Million | $-15.71 Million | -0.171x | +36.66% |
| 2023-12-31 | $100.98 Million | $-27.23 Million | -0.270x | +61.21% |
| 2022-12-31 | $109.22 Million | $-75.92 Million | -0.695x | -22.07% |
| 2021-12-31 | $180.11 Million | $-102.56 Million | -0.569x | +33.94% |
| 2020-12-31 | $105.84 Million | $-91.23 Million | -0.862x | -133.28% |
| 2019-12-31 | $198.90 Million | $-73.50 Million | -0.370x | -25.95% |
| 2018-12-31 | $140.53 Million | $-41.23 Million | -0.293x | -51.87% |
| 2017-12-31 | $82.15 Million | $-15.87 Million | -0.193x | +79.13% |
| 2016-12-31 | $12.06 Million | $-11.17 Million | -0.926x | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more